LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

The elucidation of molecular events that confer tamoxifen resistance to estrogen receptor α (ER) positive breast cancer is of major scientific and therapeutic importance. Here, we report that LEM4 overexpression renders ER+ breast cancer cells resistant to tamoxifen by activating the cyclin D-CDK4/6...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ang, Sun, Tonghua, Ma, Gui, Cao, Jiangran, Hu, Qingxia, Chen, Ling, Wang, Yanxin, Wang, Qianying, Sun, Jiafu, Wu, Rui, Wu, Qiao, Zhou, Jiaxi, Liu, Lin, Hu, Junjie, Dong, Jin-Tang, Zhu, Zhengmao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177406/
https://www.ncbi.nlm.nih.gov/pubmed/30301939
http://dx.doi.org/10.1038/s41467-018-06309-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177406/
https://www.ncbi.nlm.nih.gov/pubmed/30301939
http://dx.doi.org/10.1038/s41467-018-06309-8

Ejemplares similares